Tatjana Bilich
YOU?
Author Swipe
View article: PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development Open
Background Various cancer immunotherapies rely on the T cell-mediated recognition of peptide antigens presented on human leukocyte antigens (HLA). However, the identification and selection of naturally presented peptide targets for the dev…
View article: PCI-DB: A novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
PCI-DB: A novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development Open
Various cancer immunotherapies rely on the T cell-mediated recognition of peptide antigens presented on human leukocyte antigens (HLA). However, the identification and selection of naturally presented peptide targets for the development of…
View article: Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients Open
Cancer peptide vaccination represents a promising therapeutic approach, but has been hampered by lack of suitable antigens and restricted applicability due to different HLA backgrounds of individual patients. We here introduce a novel ware…
View article: A T-cell antigen atlas for meningioma: novel options for immunotherapy
A T-cell antigen atlas for meningioma: novel options for immunotherapy Open
Meningiomas are the most common primary intracranial tumors. Although most symptomatic cases can be managed by surgery and/or radiotherapy, a relevant number of patients experience an unfavorable clinical course and additional treatment op…
View article: Figures S1-S5 and Tables S1-S3 from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Figures S1-S5 and Tables S1-S3 from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer Open
Supplementary Figures S1-S5 Supplementary Tables S1-S3 revised
View article: Data from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Data from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer Open
Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T-cell responses in unexposed an…
View article: Figures S1-S5 and Tables S1-S3 from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Figures S1-S5 and Tables S1-S3 from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer Open
Supplementary Figures S1-S5 Supplementary Tables S1-S3 revised
View article: Data from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Data from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer Open
Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T-cell responses in unexposed an…
View article: The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma Open
View article: Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort
Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort Open
These data suggest that rapid virus clearance mediated by SARS-CoV-2-specific T cells prevents severe symptoms of COVID-19.
View article: Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer Open
Immune-checkpoint inhibitors (ICI) have transformed oncological therapy. Up to 20% of all non-small cell lung cancers (NSCLCs) show durable responses upon treatment with ICI, however, robust markers to predict therapy response are missing.…
View article: A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity Open
View article: SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function
SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function Open
Both B cells and T cells are involved in an effective immune response to SARS‐CoV‐2, the disease‐causing virus of COVID‐19. While B cells—with the indispensable help of CD4 + T cells—are essential to generate neutralizing antibodies, T cel…
View article: Phase I Trial of a Multi-Peptide COVID-19 Vaccine for the Induction of SARS-CoV-2 T-Cell Immunity
Phase I Trial of a Multi-Peptide COVID-19 Vaccine for the Induction of SARS-CoV-2 T-Cell Immunity Open
T-cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based vaccine candidate, composed of SARS-CoV-2 T-cell epitopes derived from various viral proteins, combined with the toll-like receptor 1/2 agonist XS15…
View article: Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia Open
Antigen-specific immunotherapies, in particular peptide vaccines, depend on the recognition of naturally presented antigens derived from mutated and unmutated gene products on human leukocyte antigens, and represent a promising low-side-ef…
View article: Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer Open
Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T-cell responses in unexposed and SARS-CoV-2–infected …
View article: T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals Open
Longitudinal analysis identifies SARS-CoV-2 peptide targets of durable memory T cell responses in COVID-19 convalescent individuals.
View article: Pre-existing and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients
Pre-existing and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients Open
Cancer patients, in particular patients with hematological malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T cell responses in unexposed and S…
View article: Differential kinetics of T cell and antibody responses delineate dominant T cell epitopes in long-term immunity after COVID-19
Differential kinetics of T cell and antibody responses delineate dominant T cell epitopes in long-term immunity after COVID-19 Open
Long-term immunity to SARS-CoV-2 is crucial for the development of herd immunity and the aim of vaccination approaches. Reports on rapidly decreasing antibody titers question the efficacy of humoral immunity. The relevance of T cell memory…
View article: SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition
SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition Open
The SARS-CoV-2 pandemic calls for the rapid development of diagnostic, preventive, and therapeutic approaches. CD4+ and CD8+ T cell-mediated immunity is central for control of and protection from viral infections…
View article: Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma Open
View article: Differential Kinetics of T Cell and Antibody Responses Delineate Dominant T Cell Epitopes in Long-Term Immunity after COVID-19
Differential Kinetics of T Cell and Antibody Responses Delineate Dominant T Cell Epitopes in Long-Term Immunity after COVID-19 Open
View article: Antigen Targets for the Development of Immunotherapies in Leukemia
Antigen Targets for the Development of Immunotherapies in Leukemia Open
Immunotherapeutic approaches, including allogeneic stem cell transplantation and donor lymphocyte infusion, have significantly improved the prognosis of leukemia patients. Further efforts are now focusing on the development of immunotherap…
View article: The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy Open
Antileukemia immunity plays an important role in disease control and maintenance of tyrosine kinase inhibitor (TKI)-free remission in chronic myeloid leukemia (CML). Thus, antigen-specific immunotherapy holds promise for strengthening immu…
View article: The immunopeptidomic landscape of ovarian carcinomas
The immunopeptidomic landscape of ovarian carcinomas Open
Significance Despite the revolution in cancer therapy initiated by checkpoint inhibitors, durable clinical responses remain sporadic in many types of cancer, including ovarian cancer. Understanding which antigens are essentially presented …
View article: CXCR1 Regulates Pulmonary Anti-<b><i>Pseudomonas</i></b> Host Defense
CXCR1 Regulates Pulmonary Anti-<b><i>Pseudomonas</i></b> Host Defense Open
Pseudomonas aeruginosa is a key opportunistic pathogen causing disease in cystic fibrosis (CF) and other lung diseases such as chronic obstructive pulmonary disease (COPD). However, the pulmonary host defense mechanisms regulating a…
View article: Supplementary Material for: CXCR1 Regulates Pulmonary Anti-<b><i>Pseudomonas</i></b> Host Defense
Supplementary Material for: CXCR1 Regulates Pulmonary Anti-<b><i>Pseudomonas</i></b> Host Defense Open
Pseudomonas aeruginosa is a key opportunistic pathogen causing disease in cystic fibrosis (CF) and other lung diseases such as chronic obstructive pulmonary disease (COPD). However, the pulmonary host defense mechanisms regulating a…